Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day

Alzinova is at an important stage of development. The global Phase II study of ALZ-101 is in operational start-up together with Worldwide Clinical Trials, with the aim of enrolling the first participant around the turn of 2026/2027. The study is planned to include approximately 120 participants with early Alzheimer’s disease and will evaluate the clinical efficacy, safety and tolerability of ALZ-101.

In parallel, Alzinova continues to advance its blood-based diagnostics program based on the Company’s proprietary Aβ42CC technology. The recently completed study with Amsterdam University Medical Center demonstrated measurable signals of naturally occurring antibody reactivity to toxic amyloid-beta oligomers, as well as a pattern of lower reactivity in patients with Alzheimer’s disease compared with age-matched non-Alzheimer’s controls, in line with previous observations.

During the presentation, Tord Labuda will also provide an overview of Alzinova’s strategy and the activities driving the Company’s continued development, including the clinical development of ALZ-101, the diagnostics program and the Company’s work towards potential commercial partnerships.

Redeye Neurology Day
Date: October 15, 2026
Presenter: Tord Labuda, CEO of Alzinova
Time: 10:15 CEST
Link to the presentation: https://www.redeye.se/events/1145293/redeye-theme-neurology-4

The presentation will also be available afterwards on Alzinova’s website.

For further information, please contact:
Tord Labuda, CEO
E-mail: [email protected]

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com